Canada’s upstream oil and gas sector is in intensive care
The economic damage to the energy industry is due largely to government regulatory and tax policies
Read More
Author: Steven Globerman
Federal drug-pricing plan threatens access to new medicines
There’s no escaping the fact that discovering, developing and testing new drugs costs a lot of money
Read MoreDespite government subsidies, Canadian innovation wanes
Burdensome regulation, limited competition and unfavourable taxes hold Canadian companies back
Read More
Canada’s free ride on U.S. drug development may end soon
A shift in U.S. drug pricing could cut pharmaceutical profits, meaning less money for research and development
Read More
Wake up Canada, you have a business investment crisis
There’s been no growth in years in the corporate assets that help make companies more efficient and profitable
Read More